Recaticimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Recaticimab
- adebrelimab plus albumin bound paclitaxel carboplatin and recaticimab
- IMMUNOGLOBULIN G1 (256-TYROSINE,258-THREONINE,260-GLUTAMIC ACID), ANTI-(NEURAL APOPTOSIS-REGULATED PROTEINASE 1) (HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .GAMMA.1-CHAIN), DISULFIDE WITH (3-VALINE,5-SERINE,49-SERINE,66-ASPARTIC ACID) HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .KAPPA.-CHAIN, DIMER
- IMMUNOGLOBULIN G1 (256-TYROSINE,258-THREONINE,260-GLUTAMIC ACID), ANTI-(PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) (HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .GAMMA.1-CHAIN), DISULFIDE WITH (3-VALINE,5-SERINE,49-SERINE,66-ASPARTIC ACID) HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .KAPPA.-CHAIN, DIMER
- immunoglobulin g1 256 tyrosine 258 threonine 260 glutamic acid anti neural apoptosis regulated proteinase 1 human mus musculus monoclonal hrp00130 gamma 1 chain disulfide with 3 valine 5 serine 49 serine 66 aspartic acid human mus musculus monoclonal hrp00130 kappa chain dimer
- immunoglobulin g1 256 tyrosine 258 threonine 260 glutamic acid anti proprotein convertase subtilisin kexin type 9 human mus musculus monoclonal hrp00130 gamma 1 chain disulfide with 3 valine 5 serine 49 serine 66 aspartic acid human mus musculus monoclonal hrp00130 kappa chain dimer
- immunoglobulin g1 kappa anti homo sapienspcsk9 proprotein convertase subtilisin kexin type 9 neural apoptosis regulated convertase 1 narc1 narc 1 proproteine convertase 9 pc9 monoclonal antibody recaticimab
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENSPCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, NEURAL APOPTOSIS-REGULATED CONVERTASE 1, NARC1, NARC-1, PROPROTEINE CONVERTASE 9, PC9)), MONOCLONAL ANTIBODY (RECATICIMAB)
- recaticimab
- Recaticimab
- Recaticimab (intensive)
- recaticimab [INN]
- Recaticimab [WHO-DD]
- recaticimab inn
- recaticimab who dd
- shr 1209
- Shr 1209
- SHR-1209
- shr1209
- SHR1209
- CAS registry numbers
- 2361290-85-7
- ChEMBL ID
- CHEMBL5095381
- FDA ingredient codes (UNII)
- 20IE6M67UX
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- recaticimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- proprotein convertase subtilisin/kexin type 9
- Gene symbol
- PCSK9
- Protein identifier
- Q8NBP7
- Primary target
- Yes
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Hyperlipidemias
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0021187
- Subject identifier
- D006949
- Condition
- Lipid Metabolism Disorders
- Highest recorded phase
- 1
- Condition identifier
- Orphanet:309005
- Subject identifier
- D052439
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004911
- Highest recorded phase
- 2
- Condition identifier
- HP_0003124
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001336
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005439
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021187
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0021187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_1060198
- Highest recorded phase
- 3
- Condition identifier
- Orphanet_309005
- Highest recorded phase
- 1
- Condition identifier
- Orphanet_79211
- Highest recorded phase
- 3
- NCT03634436
- NCT03944109
- NCT04844125
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (88)
- A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
- A Feasibility Study of Smoking Cessation Program in Radiation Oncology
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
- A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
- A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
- Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- Bioindicators Associated With Sarcopenia Before and After Intensive Lifestyle Intervention
- Clot Formation and Coagulation Factors Consumption in the Clearing Fluid After Arterial Catheter Blood Sampling.
- Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
- Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke
- Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
- Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model
- Digital Diabetes Remission Trial
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
- Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial
- Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
- Effects of Action Observation and Motor Imagery on Orofacial Sensorimotor Variables
- Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque
In development for (4)
- Familial hypercholesterolemia Phase 2
- Hyperlipidemia Phase 1
- Inherited lipid metabolism disorder Phase 1
- Non-small cell lung carcinoma Phase 2